ACHE and schizophrenia: Despite this strong association between cholinergic signalling and cognition in schizophrenia, agents that affect nicotine receptor function such as varenicline, or that target cholinergic neurotransmission more broadly, like acetylcholinesterase inhibitors have had disappointing results when used to treat the cognitive deficits of schizophrenia [189, 190].